A Phase 4 interventional study of Group 1 Standard of Care and Group 2 EXPAREL in Retraction of Colostomy, sponsored by Pacira Pharmaceuticals, Inc. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-06.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.
This is a phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with EXPAREL (bupivacaine liposome injectable suspension) compared with postsurgical administration of standardized intravenous (IV) morphine sulfate or Sponsor-approved equivalent for postsurgical analgesia in adult patients undergoing ileostomy reversal with general anesthesia.
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition, the patient will be ineligible if he/she meets the following criteria during surgery:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump
Drug: Group 1 Standard of Care
bupivacaine liposome injectable suspension.
Drug: Group 2 EXPAREL
Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
Also known as: bupivacaine liposome injectable suspension
Total Opioid Burden
Total opioid consumed (IV and PO) postsurgically until hospital discharge order is written or through Day 30, whichever is sooner.
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner
Health Economic Benefits
Total cost of hospitalization until the time the discharge order is written or through Day 30, whichever is sooner.
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Health Economic Benefit
Length of stay (LOS), recorded in hours, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Incidence of Opioid-related Adverse Events
Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus.
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Patient Satisfaction With Postsurgical Analgesia
Responses to one question pertaining to patient satisfaction with postsurgical analgesia
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Patient Discharged From Hospital for at Least 3 Days
Yes, if patient discharged from hospital for at least 3 days; no, if patient not discharged from hospital for at least 3 day; not reported, if applicable.
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Patient Made Unplanned Visit(s) With Any Healthcare Providers
Yes, if patient made unplanned visit(s); No, if patient did not make unplanned visits; not reported, if applicable
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Contact or Attempted to Contact Surgeon/Doctor to Discuss Recovery After Surgery
Yes, if contacted or attempted to contact; No, if did not contact and did not attempt to contact; not reported, if applicable.
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Experienced Health Problems or Changes in Health Since Hospital Discharge
Yes, if experienced health problems or changes in health; No, if did not experience health problems or changes in health; not reported, if applicable
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Time to First Opioid Administration
Time in hours to first opioid administration
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
| Milestone | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Started | 23 | 26 |
| Completed | 20 | 24 |
| Not completed | 3 | 2 |
Total opioid consumed (IV and PO) postsurgically until hospital discharge order is written or through Day 30, whichever is sooner.
| mg morphine equivalent | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Total Opioid Burden | 67.7 ± 46.64 | 38.41 ± 45.85 |
Total cost of hospitalization until the time the discharge order is written or through Day 30, whichever is sooner.
| dollars | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Health Economic Benefits | 7284.63 ± 3577.42 | 7010.16 ± 2709.56 |
Length of stay (LOS), recorded in hours, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.
| days | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Health Economic Benefit | 4 (2 to 7) | 3 (1 to 15) |
Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus.
| number of events | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Incidence of Opioid-related Adverse Events | 0.1 ± 0.22 | 0.1 ± 0.29 |
Responses to one question pertaining to patient satisfaction with postsurgical analgesia
| participants | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Extremely Satisfied | 8 | 11 |
| Satisified | 7 | 9 |
| Neither Satisfied nor Dissatisfied | 1 | 2 |
| Dissatisfied | 0 | 1 |
| Not Reported | 4 | 0 |
Yes, if patient discharged from hospital for at least 3 days; no, if patient not discharged from hospital for at least 3 day; not reported, if applicable.
| participants | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Patient Discharged From Hospital for at Least 3 Days | 16 | 22 |
Yes, if patient made unplanned visit(s); No, if patient did not make unplanned visits; not reported, if applicable
| participants who answered yes | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Patient Made Unplanned Visit(s) With Any Healthcare Providers | 2 | 4 |
Yes, if contacted or attempted to contact; No, if did not contact and did not attempt to contact; not reported, if applicable.
| participants who answered yes | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Contact or Attempted to Contact Surgeon/Doctor to Discuss Recovery After Surgery | 5 | 2 |
Yes, if experienced health problems or changes in health; No, if did not experience health problems or changes in health; not reported, if applicable
| participants who answered yes | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Experienced Health Problems or Changes in Health Since Hospital Discharge | 4 | 5 |
Time in hours to first opioid administration
| hours | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Time to First Opioid Administration | 0.7 (0.3 to 3.6) | 1.1 (0.3 to 71) |
Collected over 30 days post surgery. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 Standard of Care | — | 0/22 (0%) | 18/22 (81.8%) |
| Group 2 EXPAREL | — | 3/25 (12%) | 15/25 (60%) |
| Event | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| Gastrointestinal hemorrhageGastrointestinal disorders | 0/22 | 1/25 |
| Anastomotic leakInjury, poisoning and procedural complications | 0/22 | 1/25 |
| PeritonitisGastrointestinal disorders | 0/22 | 1/25 |
| Small intestinal obstructionGastrointestinal disorders | 0/22 | 1/25 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/22 | 1/25 |
| Systemic inflammatory response syndromeImmune system disorders | 0/22 | 1/25 |
| Renal failure acuteRenal and urinary disorders | 0/22 | 1/25 |
| Anastomatic complicationsInjury, poisoning and procedural complications | 0/22 | 1/25 |
| Event | Group 1 Standard of Care | Group 2 EXPAREL |
|---|---|---|
| DiarrheaGastrointestinal disorders | 3/22 | 3/25 |
| Wound infectionInfections and infestations | 2/22 | 1/25 |
| HypokalemiaMetabolism and nutrition disorders | 0/22 | 2/25 |
| Abdominal painGastrointestinal disorders | 1/22 | 0/25 |
| DyspepsiaGastrointestinal disorders | 1/22 | 0/25 |
| Pyoderma gangrinosumGastrointestinal disorders | 1/22 | 0/25 |
| VomitingGastrointestinal disorders | 1/22 | 0/25 |
| Edema peripheralGeneral disorders | 1/22 | 0/25 |
| Postprocedural hemorrhageInjury, poisoning and procedural complications | 1/22 | 0/25 |
| Procedural site reactionInjury, poisoning and procedural complications | 1/22 | 0/25 |
23 patients in Group 1 and 25 patients in Group 2 were enrolled. 22 patients from Group 1 and 23 patients from Group 2 were in the Safety Analysis Set (patients who underwent planned surgery).
| Age, Continuous(years) | Group 1 Standard of Care | Group 2 EXPAREL | Total |
|---|---|---|---|
| Mean | 47.1 ± 17.87 | 48.2 ± 14.53 | 47.7 ± 16.01 |
| Age, Categorical(Participants) | Group 1 Standard of Care | Group 2 EXPAREL | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 24 | 42 |
| >=65 years | 4 | 1 | 5 |
| Sex: Female, Male(Participants) | Group 1 Standard of Care | Group 2 EXPAREL | Total |
|---|---|---|---|
| Female | 8 | 11 | 19 |
| Male | 14 | 14 | 28 |
| Region of Enrollment(participants) | Group 1 Standard of Care | Group 2 EXPAREL | Total |
|---|---|---|---|
| United States | 22 | 25 | 47 |
The record gives a start of Mar 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine